Plasma and urine cyclic nucleotide levels in patients with neoplastic diseases

M. Peracchi, L. Lombardi, V. Toschi, F. Bamonti-Catena, V. Mandelli, A. T. Maiolo, L. Baldini, E. E. Polli

Research output: Contribution to journalArticlepeer-review


Plasma and/or urine cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP) levels were measured in 67 normal subjects, 55 patients with nonneoplastic diseases, and 324 patients with ten different types of cancer. There were no significant differences in plasma and urine cyclic nucleotide levels between normal subjects and patients with non-neoplastic diseases. In untreated cancer patients, plasma and urine cAMP levels were similar to those of normal subjects, whereas plasma and urine cGMP levels were markedly higher. This pattern was common to all the cancer groups studied. Chemotherapy per se did not seem to influence cyclic nucleotide levels in cancer patients. However, plasma and urine cGMP levels normalized in all patients who attained complete remission. Moreover, in acute leukemia patients who relapsed, plasma cGMP levels increased significantly with respect to the complete remission values, thus suggesting that this parameter may be useful in monitoring the response of cancer patients to treatment.

Original languageEnglish
Pages (from-to)3028-3034
Number of pages7
Issue number12
Publication statusPublished - 1984

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Plasma and urine cyclic nucleotide levels in patients with neoplastic diseases'. Together they form a unique fingerprint.

Cite this